Olivier Legrand

Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells

Hiba El Hajj, Zeina Dassouki, Caroline Berthier et al. · Blood · 2015 · 116 citations · Full text

10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Michael Lübbert, Pierre W. Wijermans, Michal Kiciński et al. · The Lancet Haematology · 2023 · 32 citations · Full text

Hematological Malignancy, Transplantation, Oncology +12

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)

Bruno Cassinat, Stéphane de Botton, Charikleia Kelaïdi et al. · Leukemia Research · 2009 · 15 citations

Hematological Malignancy, Molecular Relapse, Oncology +10

Multidrug Resistance (MDR) Gene Expression in Acute Non Lymphoblastic Leukemia: Sequential Analysis

Jean‐Pierre Marie, Olivier Legrand, Domenico Russo et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1992 · 15 citations

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

Thomas Cluzeau, Fabio Guolo, Edmond Chiche et al. · Blood Advances · 2024 · 14 citations · Full text